SERUM ACTIVIN A AND MORTALITY IN PATIENTS UNDERGOING HEMODIALYSIS

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

Presented the abstract " "
(Abstract co-author(s): )

Back

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos

E-Poster

https://storage.unitedwebnetwork.com/files/1099/288d463f7f7a31e8afffa1429d819067.pdf

Abstract Title *

SERUM ACTIVIN A AND MORTALITY IN PATIENTS UNDERGOING HEMODIALYSIS

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

The title will not be accepted if it exceeds 25 words.
Type in CAPITAL LETTERS.
Lowercase may be used for abbreviations only, for example, mRNA.

Co-author 1

Yosuke Nakagawa ysuke_nkgw@tokai.ac.jp Tokai University School of Medicine Division of Nephrology, Endocrinology and Metabolism Isehara Japan *

Co-author 2

Hiroo Takahashi h.takahashi1@kanseikai.jp Jinken Clinic Internal Medicine Ebina Japan -

Co-author 3

Yuichiro Takahashi jinken@green.ocn.ne.jp Jinken Clinic Internal Medicine Ebina Japan -

Co-author 4

Toru Hyodo thyodomd@gmail.com Medical Corporation Kuratakai Internal Medicine Hiratsuka Japan -

Co-author 5

Miho Hida m-hida@kuratakai.or.jp Medical Corporation Kuratakai Internal Medicine Hiratsuka Japan -

Co-author 6

Takao Suga t_suga@mtnet.jp Medical Corporation Showakai Internal Medicine Tokyo Japan -

Co-author 7

Takatoshi Kakuta kakuta@tokai.ac.jp Tokai University School of Medicine Division of Nephrology, Endocrinology and Metabolism Isehara Japan - Medical Corporation Showakai Internal Medicine Tokyo Japan

Co-author 8

Yusuke Tomita ytomita@tokai.ac.jp Tokai University School of Medicine Department of Transplant Surgery Isehara Japan -

Co-author 9

Michio Nakagamura m_nakamura@tokai.ac.jp Tokai University School of Medicine Department of Transplant Surgery Isehara Japan -

Co-author 10

Hirotaka Komaba hkomaba@tokai.ac.jp Tokai University School of Medicine Division of Nephrology, Endocrinology and Metabolism Isehara Japan -

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Introduction

Activin A, primarily produced by bone marrow stromal cells, immune cells, and osteoblasts, has the effect of promoting osteoclast differentiation. Serum levels of activin A increase as kidney function declines, and might be involved in bone metabolism abnormalities and vascular calcification in kidney failure. However, few studies have examined the association between activin A and mortality in kidney failure.

Methods

We analyzed a prospective cohort of 654 patients undergoing hemodialysis. The primary exposure variable was the baseline serum activin A level measured at study enrollment. The primary outcome was 8-year all-cause mortality. Mortality risk was assessed using Cox regression models adjusted for potential confounders.

Results

During a median follow-up of 7.6 years (interquartile range, 4.1–8.0 years), 229 of the 654 participants died. In a univariate analysis, serum activin A levels were not associated with mortality (Hazard ratio per doubling, 1.13; 95% confidence interval, 0.76–1.17). This result was unchanged after multivariate adjustment. Similar results were obtained for cardiovascular mortality.

Conclusion

These findings suggest that in patients undergoing hemodialysis, serum activin A levels were not associated with mortality. Further research is required to determine the role of activin A in vascular calcification and cardiovascular disease in kidney failure.

Kewords